Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 12,548 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: combined therapy treatment Clear all
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

NCT00381706
View directory record Official record
Conditions
Esophageal Cancer
Interventions
cetuximab, ECF, IC, FOLFOX
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
227
States / cities
Norwalk, Connecticut • Lewes, Delaware • Newark, Delaware + 158 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 31, 2026, 5:59 PM EDT
Completed Phase 4 Interventional

Enhanced Algorithm for Crohn's Treatment Incorporating Early Combination Therapy

NCT01698307
View directory record Official record
Conditions
Crohn's Disease
Interventions
Enhanced Treatment Algorithm, Conventional Step-care Algorithm
Other
Lead sponsor
Alimentiv Inc.
Other
Eligibility
18 Years and older
Enrollment
1,095 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Urbana, Illinois • Shreveport, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 31, 2026, 5:59 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes

NCT05038592
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic/Myeloproliferative Neoplasm
Interventions
Decitabine, Tagraxofusp-erzs
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 31, 2026, 5:59 PM EDT
Terminated Phase 3 Interventional Results available

Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone

NCT00522392
View directory record Official record
Conditions
Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
bortezomib, lenalidomide, dexamethasone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
275
States / cities
Scottsdale, Arizona • Fairfield, California • San Diego, California + 184 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Oct 31, 2026, 5:59 PM EDT
Completed Early Phase 1 Interventional

TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease

NCT02879136
View directory record Official record
Conditions
Parkinson's Disease, Idiopathic
Interventions
Methylphenidate, Physical Therapy, Atomoxetine
Drug · Other
Lead sponsor
Hubert Fernandez
Other
Eligibility
18 Years to 90 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 31, 2026, 5:59 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia

NCT00054236
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, filgrastim, cyclophosphamide, fludarabine phosphate, umbilical cord blood transplantation, methylprednisolone
Biological · Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Up to 120 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 31, 2026, 5:59 PM EDT
Recruiting Not applicable Interventional

Optimizing Telehealth-delivery of a Weight Loss Intervention in Older Adults

NCT06044571
View directory record Official record
Conditions
Obesity, Multiple Chronic Conditions
Interventions
Prescriptive, Behavioral
Other · Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
65 Years to 85 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 31, 2026, 5:59 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Investigate, Following Cataract Surgery With IOL in Conjunction With Intracanalicular Dexamethasone Insert

NCT04465864
View directory record Official record
Conditions
Glaucoma, Primary Open Angle, Cataract
Interventions
Intracanalicular Dexamethasone, 0.4 mg insert
Drug
Lead sponsor
Wolstan and Goldberg Eye Associates
Network
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Oct 31, 2026, 5:59 PM EDT
Suspended Phase 2 Interventional

Phase II Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia(CI)

NCT00790764
View directory record Official record
Conditions
Heart Disease, Blocked Arteries, Coronary Ischemia, Coronary Disease, Coronary Artery Disease, Coronary Atherosclerosis
Interventions
MESENDO, placebo
Biological · Other
Lead sponsor
TCA Cellular Therapy
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Covington, Louisiana
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 31, 2026, 5:59 PM EDT
Terminated Phase 2 Interventional Results available

Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

NCT02748564
View directory record Official record
Conditions
Metastatic Melanoma, Stage III Mucosal Melanoma of the Head and Neck, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma, Stage IVA Mucosal Melanoma of the Head and Neck, Stage IVB Mucosal Melanoma of the Head and Neck, Stage IVC Mucosal Melanoma of the Head and Neck
Interventions
Aldesleukin, Laboratory Biomarker Analysis, Pembrolizumab
Biological · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
15 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
5
States / cities
Maywood, Illinois • Bloomington, Indiana • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Oct 31, 2026, 5:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

CoMBAT Opioid Use Disorder: A Combined Medication and Behavioral Activation Treatment for People Living With Opioid Use Disorder

NCT04240093
View directory record Official record
Conditions
Opioid-use Disorder, Medication Adherence, Health Care Utilization
Interventions
Behavioral Activation (BA) Therapy, Substance Abuse and Health Navigation Counseling, Medications for Opioid Use Disorder
Behavioral · Other
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 26, 2023 · Synced Oct 31, 2026, 5:59 PM EDT
Completed Not applicable Interventional

Effect of mCIMT Casting on Speech-language Outcomes in Children With Hemiparesis

NCT04259814
View directory record Official record
Conditions
Speech and Language Disorder, Cerebral Palsy, Hemiplegia, Hemiparesis
Interventions
Speech-language therapy (SLT), Modified constraint-induced movement therapy (mCIMT)
Behavioral
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
15 Months to 7 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Oct 31, 2026, 5:59 PM EDT
Terminated Phase 2 Interventional Results available

Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)

NCT03461952
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Canadian Cancer Trials Group
Network
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Oct 31, 2026, 5:59 PM EDT
Completed Not applicable Interventional Results available

Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program

NCT02024204
View directory record Official record
Conditions
Lung Diseases, Medication Compliance
Interventions
Fluticasone propionate 230mcg for 3 Months, Current Treatment or no treatment, Salmeterol 21mcg for 3 Months
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 31, 2026, 5:59 PM EDT
Withdrawn Not applicable Interventional

iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes

NCT03446638
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
FDA-approved drug or combination of drugs, FLAG induction, 7 + 3 induction, Low-dose cytarabine, Supportive care alone, Computational biology simulations software
Drug · Other · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 31, 2026, 5:59 PM EDT
Completed Phase 2 Interventional

Chemotherapy Followed by Peripheral Stem Cell Transplantation And Biological Therapy in Treating Patients With Chronic Myelogenous Leukemia

NCT00005948
View directory record Official record
Conditions
Leukemia
Interventions
aldesleukin, recombinant interferon alfa, sargramostim, busulfan, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
2
States / cities
Denver, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 31, 2026, 5:59 PM EDT
Completed Phase 1 Interventional

CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

NCT02995655
View directory record Official record
Conditions
Myelodysplastic Syndromes, Acute Myeloid Leukemia, AML, MDS
Interventions
CX-01, Azacitidine, Bone marrow biopsy, Peripheral blood draw
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 5, 2019 · Synced Oct 31, 2026, 5:59 PM EDT
Completed Phase 1 Interventional

Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma

NCT03892044
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Richter Syndrome, Small Lymphocytic Lymphoma, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Duvelisib, Nivolumab
Drug · Biological
Lead sponsor
David Bond, MD
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 31, 2026, 5:59 PM EDT
Completed Phase 1 Interventional

A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine

NCT00741234
View directory record Official record
Conditions
Solid Tumors, Hematologic Malignancies, Myelodysplastic Syndrome
Interventions
SB939, Azacitidine
Drug
Lead sponsor
S*BIO
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Houston, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 23, 2012 · Synced Oct 31, 2026, 5:59 PM EDT
Completed Phase 1 Interventional

ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer

NCT00026364
View directory record Official record
Conditions
Colorectal Cancer
Interventions
fluorouracil, gefitinib, irinotecan hydrochloride, leucovorin calcium
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Oct 31, 2026, 5:59 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

NCT07070232
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
BNT326, Pumitamig, Itraconazole, Paroxetine
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
1,438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
19
States / cities
Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 31, 2026, 5:59 PM EDT
Completed No phase listed Observational

Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure

NCT03387163
View directory record Official record
Conditions
Heart Failure, Systolic
Interventions
Sacubitril/Valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 31, 2026, 5:59 PM EDT
Not yet recruiting Not applicable Interventional

Deep Brain Stimulation + Therapy for Stroke

NCT07849114
View directory record Official record
Conditions
Stroke, Dysarthria, Apraxia, Dysphagia, Hemiparesis After Stroke
Interventions
Boston Scientific Vercise Deep Brain Stimulation (DBS) System, Rehabilitation Training Protocol
Device · Other
Lead sponsor
Pirondini, Elvira, PhD
Other
Eligibility
22 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 31, 2026, 5:59 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).

NCT02475733
View directory record Official record
Conditions
Complicated Intra-abdominal Infections
Interventions
Ceftazidime -avibactam, Meropenem, Metronidazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
3 Months to 17 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Orange, California • San Diego, California • Toledo, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 31, 2026, 5:59 PM EDT